How much funding has Nkarta Therapeutics raised?

Nkarta Therapeutics has raised $114.0M in total funding, most recently a Series B round.

Who are Nkarta Therapeutics's investors?

Nkarta Therapeutics's investors include Samsara BioCapital, NEA, SR One, Deerfield Management, Boxer Capital, Amgen.

When was Nkarta Therapeutics founded?

Nkarta Therapeutics was founded in 2015.

Where is Nkarta Therapeutics headquartered?

Nkarta Therapeutics is headquartered in South San Francisco, California, United States.

What industry is Nkarta Therapeutics in?

Nkarta Therapeutics operates in Biotech, Oncology, Therapeutics, Healthcare, Life Sciences.

How many employees does Nkarta Therapeutics have?

Nkarta Therapeutics has 51-200 employees.

Nkarta Therapeutics

IPO

Nkarta Inc. | Natural Killer Cell Therapy Autoimmune Care

Public · South San Francisco, United States · Founded 2015 · $114.0M raised

Headquarters: South San Francisco, California
Employees: 51–200
Founded: 2015
Business Model: B2B
Website: nkartatx.com

Total Funding: $114.0M
Last Round: $114.0M Series BSep 2019
Rounds: 3
Type: Public

About

Nkarta is a clinical-stage biotechnology company advancing allogeneic, off-the-shelf natural killer (NK) cell therapies to treat autoimmune disease. Combining cell expansion and cryopreservation platforms with proprietary engineering technologies, Nkarta's lead candidate NKX019 uses donor-derived NK cells to target B cell-mediated autoimmune conditions including lupus, enabling outpatient community health setting dosing.

Summary

Nkarta Therapeutics is a Biotech company based in South San Francisco, United States, founded in 2015. It has raised $114.0M in total across 3 rounds, most recently a $114.0M Series B round in Sep 2019. Investors include Samsara BioCapital, NEA and SR One.

LinkedIn X (Twitter)